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ABSTRACT
Mismatch repair (MMR)-deficient or microsatellite instability (MSI) colorectal cancer 
includes two subtypes; Lynch syndrome and sporadic MSI cancer, both of which generate 
multiple neoantigens due to unrepaired mutations. Although such patients respond very 
well to immune checkpoint therapy, their diagnosis can be confused by low quality DNA 
samples owing to formalin fixation and/or low cancer cell content. Here we prepared 
high-quality DNA samples from in vitro-cultured cancer spheroids that consisted of the 
pure cell population. We evaluated their diagnostic power by on-chip electrophoresis, 
mutational burden assessment, and direct sequencing. Because formalin-fixed paraffin-
embedded (FFPE) tissues are widely used as the DNA source, we compared such samples 
with spheroid DNA. Additionally, we performed immunohistochemistry (IHC) for MMR 
proteins on spheroids as well as primary tumor sections. Of 111 cases of colorectal 
cancer patients, we found seven MSI-high cases in which all diagnostic results agreed on 
spheroid-based assays, whereas the results with the FFPE DNA were less reliable though 
analyzable. Importantly, there was an MSS case that appeared as MSI by IHC on primary 
tumor sections. Based on these results, we propose to employ cultured cancer spheroids 
as the source of both DNA and IHC specimens for more reliable clinical diagnosis.
INTRODUCTION
Microsatellite instability (MSI) colorectal cancer is 
a hypermutable subclass due to mismatch repair (MMR)-
deficiency. It includes two types; Lynch syndrome (LS) 
caused by germline mutations in the MMR protein genes, 
and sporadic disease without hereditary background but with 
somatic mutations and/or epigenetic changes in the responsible 
gene [1]. These mutations result from unrepaired replication 
errors including repetitive DNA sequences, causing short 
insertion-deletion (indel) mutations in mono- and di-nucleotide 
repeats, as well as other types of mutations [2, 3]. Therefore, 
MMR-deficient colorectal cancer subclass gives a strong 
indication for immune checkpoint therapy using anti–PD-1 
or –PD-L1 antibodies, with remarkable clinical efficacy [4].
While this subclass takes up 5–15% of colorectal 
cancer cases, this proportion can vary not only among 
geographic populations, but also depending on the accuracy 
of diagnostic methods [5]. Currently, two major methods 
are employed. One is immunohistochemistry (IHC) of 
MMR proteins as adopted by many institutions as the 
standard test [5, 6]. It aims to detect lack of MMR protein(s) 
as MLH1, MSH2, MSH6, and/or PMS2 [7, 8], which can 
be misleading partly because the diagnosis depends on 
‘loss’ of staining in cancer cells among co-existing stromal 
cells that show normal levels of expression.
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The other is based on the analyses of tumor genome 
that shows microsatellite instability (MSI), increased 
mutational burden and mononucleotide repeat frameshift 
mutations in some key coding genes [9, 10]. In these 
DNA analyses, tumor DNA is usually extracted from 
either frozen or, more commonly, formalin-fixed paraffin-
embedded (FFPE) tumor tissues resected surgically 
[11]. While laser-capture microdissection of frozen or 
FFPE samples can isolate cancer cell-enriched areas, this 
technique is labor-intensive, and may not be suitable for 
clinical screening service. In practice, macrodissection 
of cancer cells is widely used [4]. However, the purity of 
cancer DNA thus isolated can be compromised because 
the tumor tissues contain not only cancer epithelial cells, 
but also non-cancer stromal cells of which wild-type 
DNA may confuse the diagnosis [12]. Furthermore, DNA 
samples from FFPE tissues are chemically damaged 
significantly, often making the analysis difficult.
To overcome this problem of mixed cell population 
that composes the cancer tissue, it would be ideal if we 
can isolate only the cancer epithelial cells. To this end, it 
has become possible recently to culture and propagate the 
tumor-initiating cells (TICs, or cancer stem cells) in 3D 
matrix in vitro [13, 14]. This technique has provided not 
only cancer- but also normal epithelial-stem cells under 
rapidly growing conditions. Besides, it eliminates the 
stromal cells in the culturing process. Our current success 
rate for spheroid establishment in cancer- and normal 
epithelial-stem cells are ~90% and 100%, respectively 
[14]. Because the majority of colorectal cancer patients 
undergo resection operations of the primary tumors, fresh 
tissue samples are usually available except for very early 
or inoperable late stages. Cancer spheroid cultures offer 
us excellent test materials for genomic and expression 
analyses as well as for immunohistochemical staining of 
MMR proteins. Furthermore, we have just reported that 
chemosensitivity of spheroid-derived xenografts accurately 
reflects that of the clinical response [15]. To prepare for 
prospective studies, we are currently culturing colorectal 
cancer spheroids of all resected stage III/IV primary 
tumors at Kyoto University Hospital. This particular 
report shows one of these efforts that take the advantage of 
available spheroid cultures. In the present study, we have 
investigated the feasibility and reliability of exploiting 
cultured spheroids as the source material for MSI diagnosis.
RESULTS
Detection of microsatellite instability (MSI) in 
colorectal cancer using on-chip electrophoresis 
of satellite marker PCR products from spheroid-
derived DNA
We recently established spheroid cultures of 
colorectal cancer tumor-initiating cells (TICs, or cancer 
stem cells) as well as those of their normal epithelial stem 
cells from 111 specimens surgically resected at Kyoto 
University Hospital according to the protocol reported 
previously [13]. Clinicopathological characteristics of the 
patients are summarized in Table 1.
To improve molecular diagnosis of microsatellite 
instability (MSI) colorectal cancer, we employed an on-
chip MSI test [16], and examined the above 111 cases 
using DNA samples purified from cultured spheroid cells. 
To this end, we first extracted DNA from both cancer 
and normal epithelial spheroids of the same patients, and 
amplified by PCR five MMR-target microsatellite markers 
recommended in the Bethesda panel [1]; BAT25, BAT26, 
D2S123, D5S346, and D17S250. We then analyzed 
the PCR products by microfluidics-based on-chip 
electrophoresis in an Agilent Bioanalyzer (see Materials 
and Methods), and compared their electropherogram 
overlays regarding the peak positions between the cancer 
and normal cell DNA. This on-chip assay provides a 
higher resolution because of the shorter running time 
than the conventional fluorochrome-based assay (i.e., 
capillary electrophoresis) widely used in MSI test [16]. 
As indel mutations generated by DNA strand slippage 
during replication remained unrepaired in the genomic 
DNA of MMR-deficient cancer cells, the peak positions 
of their electropherograms often shifted from those of the 
normal epithelial cell DNA of the same patient (Figure 
1A, HC26T and HC4T). In microsatellite-stable (MSS) 
cancer cells, the peak positions of the PCR products were 
identical between cancer and normal cells, as expected 
(Figure 1A, HC51T). We also show better resolution and 
lower noise obtained by the on-chip MSI electrophoresis 
of spheroid DNA in Figure 1A. For all satellite markers 
tested, the peak heights of PCR products amplified from 
spheroid-derived DNA were significantly higher than 
those of FFPE tissue-derived DNA (Figure 1B and 1C), 
which helped identify the difference between cancer and 
normal cell peaks.
We diagnosed the MSI status according to the 
Bethesda criteria that recommended calling MSI-high 
(MSI-H) when more than 30% of cancer cell microsatellite 
markers showed different peaks from normal cell 
markers [2]. Namely, in the set of five markers above, we 
designated MSI-H when two or more had shifted cancer 
peaks (e.g., Figure 1A, HC26T and HC4T). When only 
dinucleotide repeat markers as D2S123, D5S346 and/or 
D17S250 were mutated, a secondary panel of markers 
with mononucleotide repeats (BAT40 and MYCL) was 
tested as recommended by the revised Bethesda criteria 
[1]. In some exceptional cases such as HC106T, only 
one marker (D2S123) showed clear shifts on peaks that 
reminded us of typical indel mutations. Accordingly 
we then tested two more satellite markers, and finally 
diagnosed the case as MSI-H (Supplementary Figure 1). 
Based on these results, we detected total of seven (6.3%) 
MSI-H cases and 104 MSI-L or MSS cases (30 MSI-L 
and 74 MSS).
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Mutational burden assessed by next generation 
sequencing (NGS) of spheroid-derived DNA
In MMR-deficient colorectal cancer, it is known that 
genomic mutational burden increases not only because of 
dinucleotide and mononucleotide repeats described above, 
but also due to increased mutations of various kinds [17, 
18]. One of the methods to assess such a condition is to 
estimate the density of mutations. It has been reported that 
the whole genome mutational burden can be estimated in 
coding sequence subsets [19–21]. Thus, we sequenced the 
coding regions of 409 cancer-related genes spanning 1.29 
Mb using cancer spheroid DNA samples (see Materials 
and Methods).
As described in Materials and Methods, however, 
this analysis was not so simple practically as it appeared 
in the concept. Although it was ideal to use spheroid DNA 
from the matched normal colonic epithelial cells of the 
same patients as references for cancer cells, this doubled 
the sequencing cost. As a more cost-efficient alternative, 
we referred to a database and eliminated polymorphic 
variants commonly found in the geographic population 
(see Materials and Methods, and Supplementary Figure 
2). Just in case, we also sequenced the matched normal 
epithelial spheroid DNA for two MSI-H cases, and used 
the data as additional references. These results were similar 
to those obtained by the alternative method using a normal 
population variant database (Supplementary Figure 3).
Using the variant-filtering method (Supplementary 
Figure 2), we searched for cancer-driving mutations in 
seven MSI-H and 11 MSI-L/MSS cases (Supplementary 
Tables 1 and 2, respectively). Consistent with an earlier 
report [4], the results showed significantly higher 
mutational densities in the MSI-H tumor genome than in 
the MSS, regarding both total mutations (median, 65 vs. 
8; p < 0.0001) and indel mutations (median, 11 vs. 1; p < 
0.0001) (Figure 2A, left and right, respectively). Specific 
indel mutations found in the sequenced genes are shown in 
Figure 2B and 2C. In the MSI-L or MSS cases, mutations 
of tumor DNA were found typically in APC and/or TP53 
whereas, in MSI-H tumors, they were in a variety of 
cancer-related genes.
In addition, we sequenced FFPE cancer tissue-
derived DNA from two MSI-H cases, HC4T and HC49T 
for 409 cancer related genes (Supplementary Figure 
4). The quality of the FFPE tumor DNA data were 
significantly lower than those of spheroid DNA, although 
the overall numbers of mutations/variants appeared 
similar. For example, in colon cancer HC4T, we found 
12 of 79 variants were specific to FFEP DNA in addition 
to 67 common variants including three key mutations (in 
BRAF, MTOR and RUNX1; Supplementary Figure 4). 




Age, years Median (MIN–MAX) 69 (36–89)
Amsterdam criteria 0
Bethesda criteria 0
Past history Lynch associated cancers of the colon, rectum stomach, uterine endometrium, 
small bowel and/or urinary tract
10
Familial adenomas polyposis 0
Tumor location Right side 38
Left side 43
Rectum 30




Histological grade Low grade 102
High grade 4
Mucinous 5
No. of passages from spheroid establishment to extract DNA samples
Median (MIN–MAX) 5 (1–22)
aOne patient had synchronous double cancer in sigmoid and transverse colon.
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However, the allelic frequencies for 11 of the 12 were 
< 40%. Such low frequencies were likely caused by the 
co-existing stromal cells in the FFPE tumor tissues. This is 
in a strong contrast to 20 (23%) variants that were specific 
to the spheroid DNA of which allelic frequencies for 16 of 
the 20 variants were higher than 40%, suggesting that they 
represent the majority of cancer cells. Accordingly, the 
same ambiguity can remain even if frozen cancer tissues 
Figure 1: Electropherograms of on-chip MSI analysis using spheroid-derived DNA samples. (A) HC51T. Representative 
electropherograms of an MSS case for five microsatellite markers of the Bethesda panel. Red lines show the PCR products amplified from 
the cancer cell spheroid DNA samples, whereas blue lines indicate those from the normal epithelial stem cell DNA of the same patient. 
HC26T and HC4T. Representative electropherograms of MSI-H cases. The peak patterns between tumor-initiating cells (red) and the 
normal epithelial stem cells (blue) are separated for all loci tested. The ordinate shows fluorescence intensity in arbitrary unit (FU). (B) On-
chip electropherogram of a representative case in which FFPE tumor-derived DNA sample (blue) showed much lower peaks with poorer 
resolution than spheroid-derived DNA (red) of the same patient normal mucosal stem cells (HC6N). The ordinate shows fluorescence 
intensity in arbitrary unit (FU). (C) Maximum electrophoretic peak-heights of PCR-amplified MSI markers (shown at bottom) compared 
between spheroid- and FFPE tumor-derived DNA samples. Note that spheroid-derived (Sph) DNA gave taller peaks than FFPE tumor-
derived (FFPE) DNA for all five Bethesda panel markers. ****P < 0.0001, two-tailed Mann-Whitney U test (n = 99).
Oncotarget37538www.oncotarget.com
are used as the DNA source instead of FFEP tumors. In 
this regard, some recent studies reported poor tumor cell 
purity in cancer tissue samples [12, 22, 23], one of which 
demonstrated low tumor cell contents that reduced the 
mutation frequency for key cancer mutations to < 5% [12]. 
Another study reported the discordance of sequencing 
data between cultured patient-derived cancer cells and 
primary tumors [23]. The low tumor purity samples 
reduced mutational frequency below the variant-calling 
limit in high-throughput DNA sequencing. Therefore, it 
appears that the difference in the DNA source can affect 
the accuracy of cancer diagnosis significantly.
Direct sequencing of spheroid-derived DNA for 
MMR-target key coding genes
While mutations in the non-coding satellite 
markers of MMR targets can be detected by on-
chip electrophoresis, most key functional targets that 
are affected in cancer by MMR deficiency reside in 
mononucleotide repeats in the coding sequences, often 
leaving frameshift mutations unrepaired in MSI-H 
cancer cells [5, 18]. To investigate whether above on-
chip electrophoresis results were consistent with the 
mutational status in such MMR targets, we selected four 
representative genes; TGFBR2 (A10), BAX (G8), IGF2R 
(G8), and CASP5 (A10). After amplifications by PCR on 
cancer spheroid DNA, we directly sequenced the products 
for mutations in the mononucleotide repeats (see Materials 
and Methods).
Because of the high purity of spheroid DNA both 
chemically and cell population-wise, it allowed us to detect 
not only homozygous but also heterozygous mutations in 
the MMR-target repeats by Sanger sequencing of the PCR 
products. For example, A10/A10 of TGFBR2 mutated into 
A10/A9 is ending as an A/G superimposed peak (Figure 3A, 
TGFBR2). Beyond this position, all nucleotide peaks of 
the wild-type DNA strand superimposed with those of the 
mutated strand down to the first frameshift termination 
codon. Other representative sequence data for BAX, 
IGF2R and CASP5 are also shown (Figure 3A). We noted 
that these mutations were often eliminated by variant 
calling software although they had remained in the raw 
data (Supplementary Figure 2).
Figure 2: Mutational burden estimation. (A) Total (left) and indel (right) mutational densities of MSI-H colorectal cancer spheroid 
DNA samples compared with those of MSI-L or MSS spheroid determined by NGS for 409 cancer-related genes spanning 1.29 Mb of 
the coding sequences. (B, C) List of indel mutations detected in the coding regions of 409 cancer-related genes in 11 MSI-L or MSS 
colorectal cancer spheroid DNA samples (B) and in seven MSI-H cases (C). Color codes in (B, C) indicate the locations of mutations: Red, 
in microsatellite sequences of mutational hotspots; Pink, in microsatellite sequences; Dark blue, in non-repetitive sequences of mutational 
hotspots; Light blue, in non-repetitive sequences.
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By this method, we detected frameshift mutations 
in all seven MSI-H cases (100%) regarding TGFBR2, 
whereas in six cases (86%) for BAX and CASP5, and 
in three (43%) for IGF2R. Notably, we did not detect 
such mutations in any of the MSI-L or MSS spheroids 
regarding TGFBR2 (104 cases tested) or BAX (49 cases 
tested) (Figure 4). These results strongly suggest that our 
on-chip electrophoresis of microsatellites was as accurate 
as direct sequencing of the key MMR-target coding genes 
(see below).
Immunohistochemistry (IHC) for mismatch 
repair proteins on FFPE tumor tissues and on 
cancer spheroids
For clinical diagnosis of MMR-deficient colorectal 
cancer, it is common to detect loss of MMR proteins in 
tumor tissue sections by immunohistochemistry (IHC). 
To investigate how tight the correlation is between 
the MSI status determined using spheroid DNA and 
that by MMR protein expression, we next performed 
immunohistochemistry (IHC) on four MMR proteins, 
MLH1, MSH2, MSH6, and PMS2 [7] in the primary 
tumor sections of all 111 cases. Some staining data for the 
representative cases are shown (Figure 3B). As the result, 
we detected eight MMR-deficient cases and 103 MMR-
proficient ones. Of seven MSI cases, five cases lost both 
MLH1 and PMS2 protein expression, and were assumed as 
sporadic cancer [25]. Remaining one case was confirmed 
for loss of MSH6 expression (HC137T), whereas the other 
for loss of PMS2 (HC8T), both of which were suspected 
of Lynch syndrome (Table 2). However we did not pursue 
further diagnostic tests. Notably, an MSS case with low 
mutational burden in spheroid DNA genomic analyses 
appeared as MMR-deficient by IHC (see HC13T below), 
although this difference of one in 111 cases was too small 
for statistical significance.
Colon cancer HC13T was diagnosed as MSS 
by three genomic analysis methods (on-chip MSI test, 
mutational burden assessment, and four MMR target 
mononucleotide repeats) using spheroid DNA derived 
from two independent clones as well as one FFPE tumor-
derived DNA (another DNA sample showed MSI-L) 
(Supplementary Figure 5). On the other hand, IHC of 
cancer spheroid cells of two independent spheroid clones 
demonstrated contradictory results; one MMR-proficient 
with all four MMR proteins, and the other without MLH1 
and PMS2 (Supplementary Figure 6A). Accordingly, we 
examined 14 sub-legions of the primary tumor for MLH1, 
MSH6 and PMS2. As the results, IHC for 7 of 13 sub-
lesions were evaluated as MMR-deficient because both 
MLH1 and PMS2 appeared missing (Supplementary 
Figure 6B, 6C and Supplementary Table 3). Regarding 
this discrepancy between the DNA and IHC data, it is 
worth noting that the patient was treated with oxaliplatin 
before the surgery. It has been reported that platinum-
based chemotherapeutics can affect expression of MLH1 
and MSH2 in IHC [26], and induce the methylation of 
MLH1 gene in cancer cells [27]. These results suggested 
that lack of MLH1 and PMS2 staining in this particular 
tumor was caused by platinum chemotherapy. Because this 
took place shortly before the surgery, it is reasonable to 
speculate that lack of MMR proteins did not accumulate 
mutations significantly in the whole genome. Accordingly, 
we concluded that the tumor HC13T was originally MSS, 
and that the MSI phenotype with IHC was caused by 
oxaliplatin neoadjuvant therapy. Thus, this particular 
cancer was not expected to contain enough neoantigens to 
respond to immune therapies.
It is worth noting that MSI tumor HC8T (Table 
2) lacked PMS2 staining and had heterozygous R563X 
mutation (Supplementary Figure 7). Interestingly, the 
tumor was immunostained for MLH1, and contained 
variant mutation V384D [28]. As reported, the MMR 
phenotype of MLH1 V384D mutation can vary [28]. 
Here, we found four cases of V384D mutant tumor that 
ranged from MSI-H (HC8T above) to MSI-L (HC20T; a 
double cancer with HC8T) or MSS (HC25T and HC34T; 
Supplementary Figure 7). In IHC of both the primary 
tumor and spheroid samples, MLH1 immunostaining 
was absent (–) in HC25T, moderate in HC8T (+) as 
described above, and positive (++) in HC20T and HC34T. 
Importantly, immunostaining for PMS2 that forms a 
complex with MLH1 [8] was positive in all these cases 
except HC8T that was MSI-high. It is conceivable that 
MLH1 V384D mutation affected its antigenic epitope 
detected by the antibody used here and/or its interaction 
with PMS2.
Altogether, these results of the four methods 
led us to conclude that seven of 111 cases (6.3%) were 
diagnosed as MSI-H, although eight were MMR-deficient 
as described above. As reported earlier, IHC may cause 
difficulty in diagnosis [29] and spheroid DNA analysis can 
provide more accurate diagnosis (Figure 4, and Table 2).
Spheroids provide better quality DNA more 
suitable for MSI diagnosis than FFPE-tumors
In medical research as well as in clinical services, 
DNA analyses are often performed on tumor DNA 
extracted from formalin-fixed paraffin-embedded (FFPE) 
tissues. To evaluate the quality of DNA samples derived 
from FFPE tumors compared with that from colorectal 
cancer spheroids, we performed on-chip MSI tests using 
DNA from both sources for 50 tumors. To this end, we first 
assessed the chemical purity of DNA samples obtained 
from spheroids and FFPE tumors by reading the A260/
A280 ratio. They were 1.8 and 1.7, respectively, both 
showing satisfactory purity for further analyses though the 
difference was statistically significant. We then estimated 
the DNA chain length by agarose gel electrophoresis. 
Compared with the spheroid-derived DNA samples, the 
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Figure 3: DNA sequencing analysis of some MMR-target coding mononucleotide repeats, and IHC for MMR proteins 
in primary colorectal cancer tissues or spheroid samples in MSI-H and MSI-L/MSS colorectal cancer cases. (A) DNA 
sequencing data that cover the mononucleotide repeat regions amplified from the spheroid-derived DNA samples for TGFBR2, BAX, 
IGF2R, and CASP5. For all markers, the reverse strands of the wild types (top panels), and homozygous (middle) and heterozygous 
(bottom) mutants are shown. No cases were found with IGF2R homozygous mutation. (B) Immunohistochemistry for mismatch repair 
(MMR) proteins, MLH1, MSH2, MSH6, and PMS2. The colorectal cancer (CRC) HC10T (top panels) shows a MMR-proficient (MMRp) 
example of the primary CRC section (Primary tumor), with expression of all MMR proteins. The CRC HC4T (bottom panels) shows a 
MMR-deficient (MMRd) case. Expression of MLH1 and PMS2 was not detected in the primary tumor tissue. Notably, IHC of spheroid 
cells derived from the same tumors mirrored the results with the whole tumor sections. Note that some staining of MLH1 and PMS2 in 
HC4T primary CRC sections is in the stromal cell nuclei.
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FFPE tumor DNA showed smears trailing into smaller 
chain lengths, indicating substantial fragmentation due to 
chemical damages by formalin exposure (Figure 5A).
We next tested the five satellite markers by on-chip 
electrophoresis. With the spheroid-derived DNA samples of 
50 tumors, we diagnosed five cases (10%) as MSI-H, and 
45 cases as MSI-L or MSS. With the FFPE-tumor DNA, on 
the other hand, we detected only three (6.0%) MSI-H cases, 
misdiagnosing two MSI-H cases as MSI-L, whereas one 
MSS as MSI-H. Namely, two cases (HC44T and HC4T) 
were called as MSI-L with FFPE tumor DNA despite 
that they were MSI-H with the spheroid DNA. By adding 
the results of two more satellite markers (i.e., BAT40 and 
MYCL1) in the on-chip electrophoresis, both samples showed 
more than 30% (i.e., three of seven) unstable markers even 
with the FFPE tumor DNA. The results of direct sequencing 
analysis of spheroid DNA for four mononucleotide-
repeat markers (i.e., TGFBR2, IGF2R, BAX, and CASP5) 
confirmed their final diagnosis as MSI-H (Supplementary 
Figure 8, Figure 5B, and Supplementary Table 3). These 
additional assessments were performed to resolve discrepant 
MSI status resulted from the data with spheroid and FFPE 
DNA samples. Thus, analysis on spheroid-derived DNA 
allowed us to promptly detect all MSI-H cases according to 
the Bethesda criteria with five markers (1).
On the other hand, case HC24T was diagnosed 
as MSI-H with the FFPE tumor DNA by on-chip 
electrophoresis of the five marker-panel despite it was 
MSS with the spheroid-derived DNA (Supplementary 
Figure 9A and 9B, FFPE1). Upon sequencing of spheroid 
DNA for the four MMR-target mononucleotide repeats, 
all markers were homozygous wild type (Supplementary 
Table 3). Interestingly, when we analyzed by on-chip 
MSI test the FFPE tumor DNA samples extracted from 
two more separate subregions of the HC24T tumor, 
both turned out as MSI-low or MSS (Supplementary 
Figure 9B, FFPE2 and 3). Thus, we diagnosed this 
particular case as MSS (Supplementary Table 3; see also 
the IHC results). One of the conceivable causes for this 
inconsistency regarding HC24T was the poor resolution of 
the electropherogram with the FFPE tissue-derived DNA 
as we described above, although the possibility of tumor 
microheterogeneity could not be excluded thoroughly.
Accordingly, the sensitivity (the MSI-H frequency 
by on-chip tests out of the cases diagnosed firmly by DNA 
sequencing and IHC analyses) and specificity (the frequency 
of the true MSI-H cases out of the cases designated as 
MSI-H by on-chip tests including false positives) of our 
on-chip MSI test with spheroid-derived DNA samples were 
both 100%, whereas those with the FFPE tissue-derived 
DNA was 60% and 98%, respectively. Thus, these results 
showed that spheroid-derived DNA samples provided more 
reliable data than FFPE tumor DNA.
To compare the quality of the DNA samples from 
the two sources further, we analyzed the MSI-H cases 
regarding the mononucleotide-repeat sequences of the four 
target genes that could be affected by MMR deficiency. 
The frameshift-mutation frequencies in the respective 
genes in spheroid-derived DNA were 100% for TGFBR2, 
43% for IGFR2, and 86% for BAX and CASP5 (Figure 
Table 2: MSI-H colon cancer cases assessed by (1) on-chip electrophoresis of five satellite markers, 
(2) DNA sequencing of four exoninc MMR deficiency target mononucleotide repeats, and (3) IHC 
for four MMR proteins MLH1, MSH2, MSH6 and PMS2






















HC4T H L A9/A9 WT/G7 G7/G7 A9/A9 MLH1, PMS2 MLH1, PMS2
HC8Te H H WT/A9 WT/G9 WT/G7 A9/A9 PMS2
f PMS2f
HC26T H H WT/A9 WT/G7 WT/G9 WT/A9 MLH1, PMS2 MLH1, PMS2
HC49T H H A9/A9 WT/WT G7/G7 WT/A9 MLH1, PMS2 MLH1, PMS2
HC44T H L WT/A11 WT/WT WT/G9 WT/A9 MLH1, PMS2 MLH1, PMS2
HC106T H L A8/A9 WT/WT WT/G9 WT/WT MLH1, PMS2 MLH1, PMS2
HC137T H H A9/A9 WT/WT WT/WT A8/A9 MSH6 MSH6
Mutation frequency 100% 43% 86% 86%
aH: MSI-High, L: MSI-Low
bSpheroid
cOnly spheroid DNA data were collected.
dAbsent MMR proteins in immunohistochemical staining
eMLH1 V384D mutation (see Discussion, Results and Supplementary Figure 7)
fPMS2 R563X mutation
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Figure 4: Schematic summary of the analysis results using colorectal cancer spheroids compared with those using 
FFPE tumors. (A) Mutational burden estimated by exonic sequencing of spheroid DNA for 409 cancer related genes. (B) MSI status 
judged by on-chip electrophoresis of the Bethesda panel markers. (C) Mutations in the mononucleotide repeats in coding regions of 
TGFBR2 and BAX determined using spheroid and FFPE tumor DNA. (D) IHC results of the cultured spheroids of tumor-initiating cells and 
FFPE primary tumors. Color keys are shown in boxes. See text for details.
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5B). Notably, the frequencies detected with FFPE tissue-
derived DNA samples were significantly lower than 
those with spheroid DNA (Figure 5B). It is likely that the 
compromised sensitivity of FFPE tumor DNA was caused 
by the stromal cells in cancer tissues. For example, the 
colon cancer HC49T had G7/G7 homozygous mutation 
of BAX in the spheroid-derived DNA (Figure 5C top). 
With the FFPE tumor DNA, however, peaks representing 
the wild-type stromal cells dominated, confused the 
interpretation, and led to misdiagnosis of this case as 
“wild-type” (Figure 5C bottom).
On the other hand, colon cancer HC106T was 
diagnosed as MSI-L by on-chip electrophoresis with 
FFPE tumor DNA. However, the spheroid DNA of the 
same tumor was diagnosed as MSI-H in seven-marker 
on-chip analysis because it had multiple peaks shifted 
from the normal cell DNA for D2S123, BAT40 and 
MYCL as described above (Supplementary Figure 1). 
In addition, the IHC results showed lack of MLH1 and 
PMS2 in both the whole tumor and spheroids (data not 
shown). Consistently, direct sequencing of four MMR-
target mononucleotide repeats showed that TGFBR2 and 
Figure 5: Comparison of cancer spheroid- and FFPE tumor-derived DNA samples in sequence analysis of MMR-
target coding mononucleotide repeats. (A) Agarose gel profile comparing the DNA samples from spheroid and FFPE tumors. (B) 
Mutation profiles of coding mononucleotides in four MMR-target genes for seven MSI cases analyzed with spheroid- and FFPE tissue-
derived DNA samples. Red boxes/triangles indicate mutated alleles, whereas white ones show the wild-type. Analysis with spheroid-
derived DNA enabled unambiguous identification of both alleles. However, FFPE tissue-derived DNA often gave confusing results. (C, 
top) An example of homozygous mononucleotide repeat mutation in BAX (G8 → G7), detected using the spheroid-derived DNA. Arrow 
points 8th G → T (C → A in reverse strand sequenced here). (bottom) With the FFPE tissue-derived DNA, a slightly low peak for the 8th 
G was detected after seven G peaks (C in reverse strand here). This is likely derived from DNA of the normal (i.e., wild-type) stromal cells 
rather than cancer epithelial cells.
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BAX contained homozygous and heterozygous frameshift 
mutations, respectively, although their IGF2R and CASP5 
were homozygous wild type (Table 2). Mutational burden 
assessment also showed 61 and 9 total and indel mutations, 
respectively. Again, the discrepancy of the on-chip 
electrophoresis data between the DNA samples derived 
from spheroids and FFPE tumors are likely to be explained 
by the poor quality of DNA samples from FFPE tumors.
DISCUSSION
The MMR-deficient colorectal cancer syndromes 
include mainly two types; Lynch syndrome (LS) that 
is caused by hereditary (i.e., familial) mutations in 
the MMR protein genes, and sporadic disease without 
familial background [1]. The latter can be caused either 
by somatic mutations or epigenetic inactivation of the 
MMR protein genes [17]. Diagnosis of Lynch syndrome 
patient could be performed by germline mutation analysis 
of MMR protein genes or EpCAM using DNA extracted 
from blood cells [24]. In this study, however, we did 
not distinguish these two subtypes. This is because both 
types of patients respond to immune checkpoint therapy 
very well likely because of the neoantigens generated by 
frameshift mutations in the coding regions of multiple 
genes [30]. Accordingly, it is worth the effort to maximize 
the diagnostic accuracy for identifying possible responders 
to the immune checkpoint therapy.
Notably, recent recommendations suggest that 
all colorectal cancer patients should be screened for 
MMR-deficiency first by IHC which is currently more 
economical than PCR-based DNA sequencing [6]. As we 
faced misdiagnosis (Supplementary Figure 6), however, 
IHC is not without pitfalls [29]. For example, it was 
reported that IHC of MMR proteins caused considerable 
errors; 10 of 14 cases assessed by IHC showed discrepant 
results with that of PCR analysis [29]. Besides, oxaliplatin-
induced MLH1 methylation and a specific mutation 
V384D in the same gene can give confusing results in IHC 
(Supplementary Figures 6 and 7). It is also worth noting 
that mutations in the DNA polymerase ε catalytic subunit 
gene (DPOE1) can cause hypermutational phenotype 
similar to MSI [18], although we found no such cases 
among 49 tested.
Here we evaluated multiple diagnostic measures 
using patient-derived TIC spheroid DNA and IHC, and 
demonstrated that the accuracy of MSI diagnosis was 
improved substantially. Because preparation of cancer 
spheroids from excised tumors has become less labor-
intensive and more cost-effective [14], it appears worth 
the effort considering the very high therapeutic costs for 
immune checkpoint therapy.
With more advances in technology, mutational burden 
assessment may become cheaper in a near future [31]. 
Moreover, the pure and high quality cancer spheroid DNA 
can make the analysis scheme simpler. On the other hand, 
analyses of frozen cancer tissues, not to mention FFPE ones, 
need additional improvements to eliminate noises caused by 
non-cancer stromal cells. Because tumor mutational burden 
was distinctively high in MSI-H colorectal cancer when 
determined with spheroid DNA, it is possible practically to 
reduce the sequencing depth from the current > 500 repeats 
down to > 250 or less, as reported in a similar analysis [19, 
21], which helps reduce the sequencing cost.
We have demonstrated that heterozygous mutations 
in the coding mononucleotide-repeats were detected 
unambiguously with cancer spheroid DNA, which cannot 
be attained with FFPE-tumor DNA. Although such 
heterozygous mutations do not cause loss of the gene 
functions usually, they can generate neoantigens that are 
targeted by the host immune system, which awaits further 
studies.
Some diagnostic markers are being implemented 
to stratify the cancer patients for immune checkpoint 
therapy. For example, expression of PD-1 ligands on 
cancer cell surface detected by IHC correlates with 
good response to the therapy [32]. Likewise, mutations 
in the 3’-untranslated region of the PD-L1 gene affect 
its expression level through mRNA stabilization [33]. 
Accurate diagnosis of MMR-deficient colorectal cancer 
cases in combination with other functional markers should 
help maximize the patient benefits.
Here we have evaluated multiple diagnostic 
measures using spheroid-derived DNA and spheroid IHC. 
While the final recommendation of the diagnostic method 
can be made based on the disease stage and socioeconomic 
conditions of the patient, it is worth culturing and utilizing 
the TIC spheroids from the excised primary cancer, which 
helps improve diagnostic accuracy significantly.
MATERIALS AND METHODS
Human samples
A total of 111 human colorectal cancer samples 
were obtained from patients who underwent resection 
operations between January 2015 and October 2017 at 
Kyoto University Hospital (KUHP). The study protocol 
was approved by the institutional review board of Kyoto 
University, and written informed consents were obtained 
from the patients.
Establishment and maintenance of patient-
derived epithelial spheroid lines
Patient-derived spheroids of the colorectal cancer 
and normal colonic epithelium were established and 
maintained according to previous protocols [13, 14]. 
Ninety cancer spheroid lines from 89 patients and their 
genetic mutations were reported previously [14], whereas 
21 lines from 21 patients were established thereafter in the 
present study.
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Preparation of spheroid DNA samples
Genomic DNA samples were extracted from normal 
and cancer epithelial spheroids cultured in 4 wells of 
12-well cell-culture plates (~105 cells) according to the 
previous protocol [14].
Genomic DNA preparation from formalin-fixed 
paraffin-embedded tissue sections
All cancer tissue sections were evaluated 
pathologically with H&E-stained slides to select tumor 
cell-enriched areas by a board-certified pathologist. 
Normal and cancer tissues were macrodissected with 
scalpel blades from at least three 10-µm FFPE tissue 
sections adjoining the H&E-stained section for each 
primary lesion. Dissected cancer tissue samples contained 
> 50% cancer cells. Normal colonic epithelium was 
collected from resected samples and their stem cells 
were cultured in vitro [14]. Genomic DNA was extracted 
using QIAamp DNA FFPE tissue kit (Qiagen, Hilden, 
Germany).
On-chip microsatellite instability test
Microsatellite DNA fragments were amplified 
from spheroid DNA samples using Multiplex PCR Kit 
(Qiagen) and primer pairs for the Bethesda panel markers 
[2, 34] (Supplementary Table 4). Three electrophoretic 
runs were performed for each sample (BAT25/D2S123, 
D5S346/D17S250, and BAT26) according to the standard 
protocol [16] (Supplementary Table 5). Amplified DNA 
fragments were purified with QIAquick PCR Purification 
Kit (Qiagen), applied on the DNA LabChip of the Agilent 
DNA 1000 Kit (Agilent Technologies, Santa Clara, CA, 
USA), and analyzed with an Agilent 2100 Bioanalyser 
instrument (Agilent Technologies) according to the 
previous protocol [16]. The electropherogram of each 
cancer spheroid line was overlaid with that of the normal 
epithelial spheroid line derived from the same patient. A 
marker was diagnosed as unstable if any of the cancer 
peaks for the marker shifted more than 0.5 seconds. The 
MSI status of each case was determined as follows: MSI-
high (MSI-H), with more than one unstable markers; MSI-
low (MSI-L), with one unstable marker; and MSS, with 
no unstable markers. If only dinucleotide repeat markers 
as D2S123, D5S346 and/or D17S250 were mutated, a 
secondary panel of markers with mononucleotide repeats 
(BAT40 and MYCL) was tested as recommended [1].
Sequence analysis of mononucleotide repeats in 
cancer-related coding genes
The DNA fragments containing mononucleotide 
repeats in TGFBR2 (A10), BAX (G8), IGF2R (G8), and 
CASP5 (A10) were amplified from cancer spheroid 
DNA samples using JumpStart Taq DNA Polymerase 
(Sigma-Aldrich, St. Louis, MO, USA) or PrimeSTAR 
Max DNA Polymerase (Takara Bio, Kusatsu, Japan). 
Primer sequences and PCR conditions are shown in 
Supplementary Tables 4 and 5 [35]. Purified PCR 
fragments were sequenced by Macrogen (Seoul, Republic 
of Korea).
Next generation sequencing
Next generation sequencing analyses of somatic 
cancer mutations were performed by Macrogen. In brief, 
DNA fragments that cover all exons of 409 cancer-related 
genes spanning a total length of 1.29 Mb (Ion AmpliSeq 
Comprehensive Cancer Panel; Thermo Fisher) were 
amplified from DNA samples of 7 MSI-H and 11 MSI-L 
or MSS cancer spheroid lines, and sequenced with the Ion 
Proton sequencer (Thermo Fisher).
Estimation of mutational burdens (see 
Supplementary Figure 2)
The sequencing data were processed using Ion 
Torrent Suite Software v5.0.4 (Thermo Fisher), and 
variants against the hg19 human genome reference 
were called using Torrent Variant Caller v5.0.4 (Thermo 
Fisher). Possible cancer-specific mutations were selected 
through the following processes. The polymorphic alleles 
in 1,200 Japanese individuals were removed from each 
variant [36]. Only variants in the coding regions with 
> 20% frequency without polymorphism were scored. 
Erroneous mutations were eliminated by surveying their 
coverage tracks on Integrative Genomics Viewer software 
v2.3 (Broad Institute).
Histological specimens
Formalin-fixed paraffin-embedded (FFPE) tumor 
specimens were prepared by the standard procedures in 
Department of Diagnostic Pathology, Kyoto University 
Hospital. A board-certificated pathologist selected 
multiple and separate cancer lesions from a single tumor. 
Specimens of FFPE cancer spheroids were prepared 
as previously reported [14]. These specimens were 
sectioned at 4-μm thickness, and stained with H&E or 
immunostained for MLH-1 (M1, Ventana, Tucson, AZ, 
USA), MSH2 (G219-1129, Ventana), MSH6 (EPR3945, 
Abcam, Cambridge, UK), or PMS2 (EPR 3947, Ventana) 
followed by hematoxylin counterstaining for nuclei.
Agarose gel electrophoresis of genomic DNA
Genomic DNA samples from spheroids and FFPE 
tissues were electrophoresed on a 0.7% agarose gel. 
The gel was stained with ethidium bromide, and DNA 
fragments were visualized using Gel Doc XR+ (BioRad, 




Statistical analyses were conducted using GraphPad 
Prism 6 (Graph Pad Software, La Jolla, CA, USA). Mann-
Whitney test was applied to compare DNA quality and 
electropherogram peak heights between spheroid- and 
FFPE-derived samples, and to compare total or indel 
mutational burden between MSI-H cases and MSI-L or 
MSS cases.
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